ABCL
Abcellera Biologics IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$1.61B
P/E Ratio
—
EPS
$-0.48
Beta
1.03
52W High
$6.79
52W Low
$2.75
50-Day MA
$4.58
200-Day MA
$4.23
Dividend Yield
—
Profit Margin
-181.70%
Forward P/E
27.55
PEG Ratio
—
About Abcellera Biologics Inc
AbCellera Biologics Inc. develops an antibody discovery platform. The company is headquartered in Vancouver, Canada.
Fundamentals
| Revenue (TTM) | $79.21M |
| Gross Profit (TTM) | $-107.62M |
| EBITDA | $-188.28M |
| Operating Margin | -692.00% |
| Return on Equity | -14.70% |
| Return on Assets | -9.99% |
| Revenue/Share (TTM) | $0.26 |
| Book Value | $3.09 |
| Price-to-Book | 1.72 |
| Price-to-Sales (TTM) | 20.32 |
| EV/Revenue | 15.72 |
| EV/EBITDA | 5.30 |
| Quarterly Earnings Growth (YoY) | 45.90% |
| Quarterly Revenue Growth (YoY) | 96.30% |
| Shares Outstanding | $305.38M |
| Float | $205.32M |
| % Insiders | 22.80% |
| % Institutions | 43.19% |
Historical Volatility
HV 10-Day
104.43%
HV 20-Day
105.69%
HV 30-Day
100.47%
HV 60-Day
79.47%
HV Rank
96.8%
Volatility is currently expanding
Analyst Ratings
Consensus ($10.43 target)
1
Strong Buy7
Buy1
HoldMore HEALTHCARE Stocks
Data last updated: 6/13/2026